The Australasian Lung Cancer Trials Group (ALTG), an initiative of Lung Foundation Australia, is dedicated to reducing the incidence, morbidity and mortality of lung and other thoracic cancers through coordinating and facilitating quality research. Three new clinical trials have recently been initiated in advanced thoracic malignancies and supportive palliative care.
A clinical trial for patients living with with histologically or cytologically confirmed NonSmall Cell Lung Cancer (NSCLC) with EGFR
mutation. Phase II, single arm trial to assess the efficacy and tolerability for patients with the use of Durvalumab and Tremelimumab with Chemotherapy in metastatic EGFR nonsmall cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors. The findings from this trial will provide information on the tolerability and effectiveness of combining Durvalumab and Tremelimumab with Chemotherapy in patients with metastatic EGFR non small cell lung cancer (NSCLC) after they have progressed on EGFR Tyrosine Kinase Inhibitors.
A clinical trial of patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC) in the United States showed early referral to palliative care improves quality of life, survival and use of health care resources. In the PEARL study researchers will investigate in Australia if early referral to palliative care improves pain, cough and breathlessness in people with advanced lung cancers.
To find out more about these clinical trials including recruitment criteria, talk to your oncologist or visit altg.com.au.